DIABETIC MACULAR EDEMA

This early-stage trial tests an experimental drug called ASKG712, given as an eye injection, for people with diabetic macular edema (DME) — a condition that causes vision loss in people with diabetes. The study involves 26 participants and focuses on safety and how the drug moves…

This study tests a medicine called faricimab in people with diabetic macular edema, a condition that causes vision loss. It focuses on Black, Hispanic, Native American, and Asian Indian patients who have not been treated before. The goal is to see if the medicine improves eyesigh…

This study tests whether giving two steroid implants close together at the start of treatment, followed by injections only as needed, can improve vision more than the usual approach in people with diabetic macular edema. The trial includes 53 adults with significant swelling in t…

This study looks at adults with diabetic macular edema (DME) whose vision hasn't improved enough with standard anti-VEGF injections. They receive a dexamethasone implant (DEX-I) that slowly releases steroid into the eye. Researchers will track how many extra anti-VEGF shots they …

This study tests a new medicine (RO7446603) for people with diabetic macular edema, a condition that causes vision loss due to diabetes-related fluid buildup in the eye. The trial has two parts: first, checking safety of the drug alone or with existing treatments (aflibercept or …

This study tests a gene therapy called 4D-150 for people with diabetic macular edema, a condition where fluid builds up in the eye and blurs vision. About 72 adults who still need regular eye injections will receive either the gene therapy or standard treatment. The goal is to se…

This early-stage study tests a new medicine called RO7497372 for people with diabetic macular edema (DME), a condition that causes blurry vision. The study involves 151 participants who receive injections into the eye to check the drug's safety and how the body processes it. The …

This study tests a flexible 'treat-and-extend' approach for faricimab injections against the standard fixed schedule in people with diabetic macular edema. The goal is to see if the flexible schedule can maintain vision improvement while reducing the number of injections. About 4…

This study tests whether a pre-filled syringe is as safe as the standard vial when giving an eye injection for wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. About 120 people will receive the drug ONS-5010 (bevacizumab) either from…

This study tests a higher dose of the drug aflibercept given as an eye injection every 4 weeks in about 1,100 adults with wet age-related macular degeneration (AMD) or diabetic macular edema (DME). All participants have been treated before with similar drugs. The main goal is to …

This study tests a drug called tonabersat against a placebo in 128 adults with diabetic macular edema (swelling in the back of the eye) who still have good vision. The main goal is to see if the drug reduces retinal thickness. Participants take the drug or placebo and are monitor…

This study is observing 6,000 adults already receiving Roche eye treatments for conditions like wet macular degeneration and diabetic eye swelling. It does not test new drugs or change standard care. Instead, it collects long-term data on vision changes, treatment patterns, and s…

This study watches 110 adults with diabetic macular edema who are already prescribed OZURDEX by their doctor. Researchers will track side effects and eye health for 2 years to see how safe the treatment is in real-world use. No extra tests or treatments are required beyond normal…